Week In Review: Global Cooperation Increases Patient Safety

Week In Review: Global Cooperation Increases Patient Safety

03.02.13 | By Christian Clymer

PhRMA executives were busy this week. At the Economist's 2013 Pharma Summit in London, global pharmaceutical and health experts discussed the sector. PhRMA President and CEO John Castellani gave the closing remarks where he addressed the challenges confronting the biopharmaceutical research industry and the ways in which organizations around the world can come together to overcome them.

Specifically, he outlined four things the industry needs to do to continue to innovate and meet patients' needs. These four pillars are interdependent, and without them, it's difficult to see how we make significant medical advances in the future. They include:

  • A business environment that inspires and rewards smart risk-taking and investment
  • A vibrant, collaborative and modern scientific ecosystem to support innovation
  • A transparent regulatory system that evolves with advancements in science and technology
  • An environment where innovative medicines are properly valued

Back in the U.S., Scott LaGanga, Vice President of Advocacy and Public Affairs at PhRMA and Executive Director at Partnership for Safe Medicines, spoke about the importance of protecting patients. At the Institute for Policy Innovation (IPI) and the Center for Medicine in the Public Interest (CMPI), he highlighted the rise of global prescription drug counterfeiting and the need for nations to come together to combat this dangerous problem.

Last year in the U.S., five phony online pharmacies were prosecuted and 370 doctors in 38 states were warned that they may have purchased counterfeit medications. It's global issue because the problem can originate in one country and affect patients half way around the world. It's through collaboration that will be able to ensure patient safety.

In our highly connected world, cooperation among nations is the only way to overcome the hurdles that the pharmaceutical industry faces, and our executives will continue to travel and speak to new audiences to ensure people understand what these challenges mean for patients. We encourage you to check back with us on The Catalyst to learn more about our issues and what we're doing to address them.

More On PhRMA — powered by PhRMApedia


Cost in Context